The United Kingdom and the United States have forged a major trade agreement that will guarantee no import taxes on British medicine exports going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the public health system. This commitment secures that tariffs on these crucial exports will be held at zero for a period of three years.
This development follows previous statements to significantly raise duties on branded drug imports, with increases mentioned up to 100%.
"This deal with the Britain bolsters the international landscape for new treatments and brings much-needed balance to American-British medicine commerce," a statement noted.
Trade Importance
Drugs constitute one of the Britain's biggest goods shipped to the United States, which is easily the largest destination for leading companies like GSK and AstraZeneca.
Trade data show that in the year prior to the third quarter, the UK shipped pharmaceutical products valued at billions to the US. This amount accounted for 17.4% of British export trade in that span.
"This agreement protects work, stimulates funding and sets the stage for the UK to establish itself as a international leader for medical research," a government official commented.
Specific UK Commitments
The agreement includes several specific changes from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must return to the NHS to control costs will be limited at fifteen percent. In the past, repayments exceeded 20%.
Industry Background
This agreement follows a protracted row between the drug companies and the British authorities over spending levels and approval rates.
These tensions were intensified by claims that American customers were charged significantly more for the same drugs than consumers in the UK and Europe.
In recent months, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been pledged toward US facilities.
One official publicly accepted that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the past decade.
